How Claims Data Volatility Is Impacting Biopharma: A 2025 Industry Snapshot
The data volatility ripple effect
68% of biopharma leadersreported experiencing disruptions in their real-world claims data in the past year. The volatility leads to flawed analytics, delayed timelines, and lost productivity.
A new survey sponsored by McKesson Compile™ uncovers how volatility in real-world claims data is impacting commercialization — and how teams are adapting.
Snapshot: Erroneous insights
The graphic below provides a preview of the analysis featured in the report. Here, 73% of respondents claimed data issues led to false insights. Among them, 86% were forced to reverse a business decision. This is only a glimpse into the consequences of data volatility.
Download the report
Get the full report to explore:
Where data volatility is hitting commercial teams the hardest and why it often goes undetected
How disruptions are delaying decisions, increasing rework, and introducing risk
What steps biopharma leaders are taking to strengthen data reliability and vendor accountability
What to look for in a data vendor when it comes to data disruption
Fill out the form to access the complete survey findings and strategic recommendations.
